Liraglutide restored blood vessel function in diabetic mice while also rebalancing their gut microbiome, and the short-chain fatty acid butyrate (produced by the restored bacteria) independently improved nitric oxide signaling in blood vessel cells.
GLP-1RA-microbiome-vascular axisLiraglutide enriched butyrate-producing gut bacteria (Lachnospiraceae, Lactobacillus) while restoring endothelial nitric oxide signaling — linking gut health to blood vessel function
What the researchers found
In db/db diabetic mice treated with liraglutide (300 μg/kg/day IP for 2 weeks):
- **Vascular function**: Endothelium-dependent relaxation was significantly improved in mesenteric resistance arteries.
- **Endothelial signaling**: In high-glucose-treated HUVECs, liraglutide restored eNOS phosphorylation (at Ser1177) and nitric oxide production.
- **Gut microbiome**: Diabetes caused marked dysbiosis with reduced alpha diversity and depletion of short-chain fatty acid (SCFA)-producing taxa. Liraglutide substantially restored microbial diversity and enriched beneficial genera including Lachnospiraceae and Lactobacillus.
- **Butyrate connection**: Low-dose butyrate independently enhanced nitric oxide production in endothelial cells, supporting a causal link between microbiome changes and vascular improvement.
Why it matters
Cardiovascular disease is the leading cause of death in diabetes, and endothelial dysfunction is where it starts. This study reveals a novel mechanism by which GLP-1 drugs protect the heart: by reshaping gut bacteria to produce more butyrate, which helps blood vessels make nitric oxide. This 'drug-microbiome-vessel axis' could explain why GLP-1 agonists have such strong cardiovascular benefits in clinical trials — and could inspire microbiome-targeted add-on therapies.
How the study worked
Male db/db mice (a genetic diabetes model) and non-diabetic controls received liraglutide (300 μg/kg/day IP) or saline for 2 weeks. Vascular function was measured in mesenteric resistance arteries using wire myography. Endothelial nitric oxide signaling was assessed in HUVECs (human umbilical vein endothelial cells) exposed to high glucose ± liraglutide or butyrate. Gut microbiota composition was analyzed by 16S rRNA gene sequencing.
What this study cannot tell us
The study used intraperitoneal (not subcutaneous) liraglutide administration, which may produce different pharmacokinetics than the clinical route. The 2-week treatment duration is short relative to chronic human use. The butyrate-NO connection was demonstrated in cell culture only, not confirmed as the in vivo mediating mechanism. Gut microbiome changes are correlational — a fecal transplant experiment would be needed to prove causation.
How to read the evidence
This is a preclinical study combining in vivo mouse experiments with in vitro cell culture work and 16S rRNA microbiome sequencing. While the multi-pronged approach is rigorous, the causal chain from microbiome to vascular function was not definitively established.
When this study was published
Published in 2026, this is a very recent study at the cutting edge of the GLP-1 agonist-microbiome-cardiovascular connection — a rapidly evolving research area.
The bigger picture
The gut-vascular axis is an emerging concept in cardiometabolic medicine. This study adds GLP-1 agonists as key modulators of this axis, connecting three research fields: peptide pharmacology, microbiome science, and vascular biology. If confirmed, it suggests that probiotics, prebiotics, or butyrate supplements could potentially complement GLP-1 therapy for enhanced cardiovascular protection in diabetes.
Questions still open
- Would supplementing butyrate or butyrate-producing probiotics alongside GLP-1 therapy enhance cardiovascular outcomes in diabetic patients?
- Is the microbiome-vascular connection unique to liraglutide, or do other GLP-1 agonists like semaglutide produce similar microbial shifts?
- Does the gut-vascular axis mechanism explain why some diabetic patients respond better to GLP-1 agonists than others — based on their baseline microbiome?
Common questions
How could gut bacteria affect blood vessel health?
Does this mean taking probiotics could help diabetic blood vessels?
Read the original research
Liraglutide alters gut microbiota and improves endothelium-dependent relaxation in db/db mice.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 196, 119042
Citation
Oh, Eun Yi; Suh, Soo Hwan; Byeon, Seonhee; Lee, Jooyong; Lee, Young-Ho; Choi, Soo-Kyoung. (2026). Liraglutide alters gut microbiota and improves endothelium-dependent relaxation in db/db mice.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 196, 119042. https://doi.org/10.1016/j.biopha.2026.119042